Denali Therapeutics Inc. (DNLI) stock
DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$18.74−0.15 (-0.79%)
Close on Nov 13, 2026Market cap $3.00BP/E –Yield –
Denali Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Denali Therapeutics's total assets was $1.16B at Jun 30, 2026. For fiscal 2025 it was $1.14B, down 16.7% from the year before. The highest annual figure on record is $1.60B in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.14B | -16.7% |
| FY2024 | Dec 31, 2024 | $1.37B | +19.1% |
| FY2023 | Dec 31, 2023 | $1.15B | -21.0% |
| FY2022 | Dec 31, 2022 | $1.46B | +4.0% |
| FY2021 | Dec 31, 2021 | $1.40B | -12.5% |
| FY2020 | Dec 31, 2020 | $1.60B | +190.0% |
| FY2019 | Dec 31, 2019 | $553.23M | -16.4% |
| FY2018 | Dec 31, 2018 | $661.98M | +36.0% |
| FY2017 | Dec 31, 2017 | $486.72M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.16B | -0.7% |
| Q1 FY2026 | Mar 31, 2026 | $1.27B | -0.4% |
| Q4 FY2025 | Dec 31, 2025 | $1.14B | -16.7% |
| Q3 FY2025 | Sep 30, 2025 | $1.06B | -27.4% |
| Q2 FY2025 | Jun 30, 2025 | $1.17B | -22.4% |
| Q1 FY2025 | Mar 31, 2025 | $1.27B | -19.6% |
| Q4 FY2024 | Dec 31, 2024 | $1.37B | +19.1% |
| Q3 FY2024 | Sep 30, 2024 | $1.45B | +17.6% |
| Q2 FY2024 | Jun 30, 2024 | $1.50B | +15.1% |
| Q1 FY2024 | Mar 31, 2024 | $1.58B | +12.2% |
| Q4 FY2023 | Dec 31, 2023 | $1.15B | -21.0% |
| Q3 FY2023 | Sep 30, 2023 | $1.24B | +0.7% |
| Q2 FY2023 | Jun 30, 2023 | $1.31B | +1.0% |
| Q1 FY2023 | Mar 31, 2023 | $1.41B | +6.7% |
| Q4 FY2022 | Dec 31, 2022 | $1.46B | +4.0% |
| Q3 FY2022 | Sep 30, 2022 | $1.23B | -15.3% |
| Q2 FY2022 | Jun 30, 2022 | $1.29B | -14.4% |
| Q1 FY2022 | Mar 31, 2022 | $1.32B | -14.7% |
| Q4 FY2021 | Dec 31, 2021 | $1.40B | -12.5% |
| Q3 FY2021 | Sep 30, 2021 | $1.45B | +35.5% |
| Q2 FY2021 | Jun 30, 2021 | $1.51B | +133.2% |
| Q1 FY2021 | Mar 31, 2021 | $1.55B | +122.4% |
| Q4 FY2020 | Dec 31, 2020 | $1.60B | +190.0% |
| Q3 FY2020 | Sep 30, 2020 | $1.07B | +77.5% |
| Q2 FY2020 | Jun 30, 2020 | $647.34M | +1.5% |
| Q1 FY2020 | Mar 31, 2020 | $695.87M | +2.8% |
| Q4 FY2019 | Dec 31, 2019 | $553.23M | -16.4% |
| Q3 FY2019 | Sep 30, 2019 | $602.98M | +10.7% |
| Q2 FY2019 | Jun 30, 2019 | $637.60M | +11.5% |
| Q1 FY2019 | Mar 31, 2019 | $676.60M | +10.2% |
| Q4 FY2018 | Dec 31, 2018 | $661.98M | +36.0% |
| Q3 FY2018 | Sep 30, 2018 | $544.48M | – |
| Q2 FY2018 | Jun 30, 2018 | $572.06M | – |
| Q1 FY2018 | Mar 31, 2018 | $613.95M | – |
| Q4 FY2017 | Dec 31, 2017 | $486.72M | – |
See a number that looks wrong?